Scintillon Institute

Chemtron Biotech, Inc. is a professional manufacturer of rapid in-vitro diagnostic tests, with manufacturing facilities in both San Diego, CA and Shanghai, China. Their state-of-the-art facilities in San Diego span 14,000 sq. ft., equipped with in-house manufacturing capabilities and a capacity of up to 3 million devices per year, while their China facility covers 200,000 sq. ft. and includes manufacturing, research and development laboratories, and domestic and international marketing.Generated from the website

Quidel Corporation, based in San Diego, CA, is a leading provider of diagnostic healthcare solutions. They specialize in developing and manufacturing tests for various gastrointestinal disorders, including colorectal cancer. With their QuickVue iFOB test, they aim to detect blood in stool specimens, which can be an indication of colorectal cancer and other gastrointestinal conditions. Quidel Corporation is dedicated to providing accessible and accurate diagnostic tools to help individuals and their physicians in the early detection and diagnosis of colorectal cancer. Quidel Corporation's commitment to improving healthcare extends beyond their diagnostic solutions. They support organizations like Susie's Cause - The Susan Cohan Kasdas Colon Cancer Foundation, the Colon Cancer Alliance, and The Colon Club, which advocate for colon cancer awareness and provide support to survivors. With their expertise and dedication, Quidel Corporation plays a vital role in the fight against colorectal cancer, one of the most common cancers in the United States.Generated from the website

Cenna Biosciences, LLC, based in La Jolla, California, is a biopharmaceutical company dedicated to developing innovative treatments for Alzheimer's disease. Their lead product, Nubytide, is a potential disease-modifying peptide offering a proactive therapy aimed at preventing and treating Alzheimer's, targeting inflammation and Tau pathology in the brain. With a strong intellectual property portfolio and significant market potential, Cenna aims to make Nubytide accessible to every patient suffering from Alzheimer's disease. The company has received a Phase II SBIR grant from the National Institutes of Health to support the early clinical development of Nubytide, highlighting its commitment to addressing the growing global Alzheimer's epidemic. Generated from the website